{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-000026","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2022-01-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.972121+00:00","generated_at":"2026-06-27T20:50:03.906622+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"TG Therapeutics expands credit facility to $200M, extends maturity to 2026","bullets":["Loan increased from $60M to $200M; initial $70M drawn, $7.8M used to refinance existing balance.","Maturity extended to Jan 1, 2026; interest-only period extended to Feb 1, 2025 (extendable to Aug 1, 2025).","Interest rate: prime + 2.15% (floor 5.40%); warrants issued for 115,042 shares at $17.95, 7-year term.","Financial covenants: minimum cash from Oct 15, 2022; market cap/cash covenants from July 1, 2023 if drawn >$70M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-000026","json":"https://secwatch.observer/filing/0001558370-22-000026.json","markdown":"https://secwatch.observer/filing/0001558370-22-000026.md","text":"https://secwatch.observer/filing/0001558370-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022000026/0001558370-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022000026/tgtx-20211230x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T20:50:03.906622+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}